Ignite Creation Date:
2024-05-06 @ 6:36 PM
Last Modification Date:
2024-10-26 @ 2:51 PM
Study NCT ID:
NCT05725915
Status:
RECRUITING
Last Update Posted:
2023-02-13
First Post:
2023-01-16
Brief Title:
Prediction Model of ICIs Combined With Chemotherapy in Advanced NSCLC
Sponsor:
Beijing Red Clove Public Welfare Development Center
Organization:
Beijing Red Clove Public Welfare Development Center
Study Overview
Official Title:
Multiparameter Prediction Model of Immune Checkpoint Inhibitors Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer a Real-world Study
Status:
RECRUITING
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The reliable predictive markers to identify which patients with advanced non-small cell lung cancer tumors will achieve durable clinical benefit for chemo-immunotherapy are needed This study is a real world study aiming to establish a multi-parameter model to predict the efficacy of immune checkpoint inhibitorICI combined with chemotherapy and to explore the correlation and predictive value of each single biomarker so as to assist physician to select patients who may benefit for a long time as early as possible and guide clinical accurate treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None